OLPX · Olaplex Holdings, Inc.

Current Thesis

The watch-for-the-inflection thesis is closed by event. On 2026-03-26 Olaplex agreed to be acquired by Germany's Henkel for $2.06/share in all cash (~$1.4B equity value) a ~55% premium to the 2026-03-25 close (~$1.33) and ~45% over the 30-day VWAP. The stock now trades pegged at ~$2.04, roughly 1% below the cash price, and that ~$2.06 ceiling is hard: a cash-pegged equity cannot trend, so there is no narrative leg to buy. Majority holder Advent International adopted the merger by written consent on 2026-05-04, removing shareholder-vote risk; the only open gate is antitrust clearance in the US, Germany, and Australia, with management guiding to a 2H-2026 close (outside date 2027-09-30). For a narrative-momentum book this is dead money at most a ~1% risk-arb spread, which is not this account's edge. The prior turnaround question (Q1 the binary) was answered twice over: the Q1 2026 print on 2026-05-11 finally went green, but the takeout makes operations irrelevant to price.

Bull Case

• Deal is signed and shareholder-approved (2026-03-26 / 2026-05-04): All-cash $2.06, Advent (majority) adopted by written consent 2026-05-04 no shareholder vote can derail it. The remaining path to $2.06 is regulatory only.
• Operations are healthy enough to leave Henkel no out (Q1 reported 2026-05-11): Net sales $99.4M +2.5% YoY, gross margin 72.1%, Professional +12.3%, DTC +13.8%. First green comp after the multi-year decline streak a material-adverse-change exit is hard to argue.
• Clean balance sheet for a takeout (as of 2026-03-31): $326.2M cash vs $352.5M long-term debt near-zero net debt against $1.4B equity value. No financing or solvency complication.
• Low antitrust complexity: A ~$1.4B prestige-hair-care deal; Henkel's only real overlap is Schwarzkopf professional, a thin slice. Routine clearance is the base case in US/Germany/UK/Australia.

Bear Case

• Upside is capped at $2.06: At ~$2.04 the gross spread is ~1% for a 2H-2026 close a bond-like arb return, not a momentum return. There is nothing here for a book that buys accelerating tape.
• Deal-break tail resets the stock to ~$1.33: A $40.44M termination fee, an outside date stretching to 2027-09-30, and antitrust review in Henkel's home market (Germany) plus the UK CMA are the live risks. A second request or block sends the equity back toward the pre-announcement ~$1.33.
• The underlying business never actually inflected: Specialty Retail still fell 13.3% in Q1 2026 and US sales declined 3.5%; the modest +2.5% group comp leaned on Professional/DTC. The takeout bailed out a story that hadn't fixed shelf loss to K18/Redken/L'Oréal private-label.
• Going dark (2026-05-11): Guidance withdrawn and the earnings call cancelled into the pending deal. No information flow, no catalysts to trade.

Setup & Price Structure

• Flat arb peg, ~$2.04 vs $2.06 cash: The chart is a pinned line, not a trend. RSI, moving-average reclaim, breakout-retest none apply to an equity locked to a fixed cash price.
• No momentum setup exists or can exist pre-close: There is no compression breakout, volume expansion, or higher-low to engage; the deal removed price discovery.
• The only structural tell that matters is a downside break: A daily close below ~$1.80 would mark the market pricing real deal risk. Absent that, the range is a tight ~$2.00–$2.06 drift toward consideration as close approaches.

Catalyst Calendar (next 30 days)

• No dated, tradeable catalyst within 30 days of 2026-06-07. The earnings call is suspended; no investor day is scheduled into close.
• Antitrust clearances (US / Germany / UK / Australia) pending, no announced decision dates; any clearance headline is binary-flavored but expected to pass. Target close 2H 2026.
• Merger outside date: 2027-09-30 the legal backstop, not a near-term event.
• Q2 2026 results: ~early-to-mid August 2026 (est.) outside the window and likely a minimal release given the pending transaction.

What Would Change Our Mind

• A merger-termination announcement (either party) stock craters toward the pre-deal ~$1.33 and reverts to a broken-IPO chart. Only then does a fresh, much-lower turnaround setup become worth scanning, and only with a clean weekly higher-low plus a green comp in hand.
• An antitrust second request or UK CMA Phase 2 referral the spread widens into a genuine risk-arb; still outside this book's mandate, but worth re-rating the break probability.
• Absent a break, nothing re-opens a momentum thesis on close the equity simply ceases to exist at $2.06. There is no scenario where this name becomes an accelerating-narrative buy before deal resolution.

Correlation Notes

• Decoupled from beauty/consumer-discretionary peers (ELF, COTY, EL) and from the broad tape price is pinned to deal completion, driven by antitrust headlines and Henkel's (HEN.DE / HENKY) M&A stance, not sector flow.
• Near-zero beta to SPY/XLY until close or break an idiosyncratic merger-arb instrument, not a momentum vehicle. Treat any correlation it shows to the consumer complex as coincidental until the deal resolves.